LEARN ABOUT Infliximab :
an unbranded biologic

Janssen’s unbranded Infliximab Is REMICADE ® Without the Brand Name

A prescription medicine that
is the same as the biologic
medicine REMICADE ®

Treatment list

Approved to treat the same
conditions as REMICADE®

Available in the same strength and same
dosage form as REMICADE®, and given
intravenously the same as REMICADE®

Same as REMICADE® except for the brand name and package

Unbranded Infliximab can support the treatment plan you and your doctor have chosen

Insurance companies may ask some patients
to switch their therapy even though they may be doing well
medically on their current therapy

If your coverage for REMICADE® has changed,
unbranded Infliximab offers you a treatment
option that is the same product as REMICADE®

Understanding unbranded biologics

Unbranded biologics are not biosimilars. One Difference Between the Two is:

unbranded biologic

An unbranded biologic is the same as the
brand-name product

biosimilar to reference product

A biosimilar must be highly similar to a brand-name
product and must show that there are no
clinically meaningful differences in terms of safety
and effectiveness

ISI button expand

© Janssen Biotech, Inc. 2023. All rights reserved.

This site is published by Janssen Biotech, Inc., which is solely responsible for its contents. The material on this site is intended only as informational or as an educational aid and it is not intended to be taken as medical advice. The ultimate responsibility for patient care resides with a healthcare professional.

This information is intended for the use of patients and caregivers in the United States and Puerto Rico only. Laws, regulatory requirements, and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here may not be appropriate for use outside the United States and Puerto Rico.

Third-party trademarks used herein are trademarks of their respective owners.

Privacy Policy | Cookie Policy |--> Contact Us

Last updated September 2023

Infliximab

The information contained in this section of the site is intended for US healthcare professionals only. Please click the appropriate link below.

You are leaving Infliximab.com

Thank you for visiting www.infliximab.com.

By clicking “continue” below, you will be taken to a Web site that may contain links or references to other Web sites to which our Privacy Policy may not apply. We encourage you to read the Privacy Policy of every Web site you visit.

You are solely responsible for your interactions with such Web sites.

You are leaving Infliximab.com

Thank you for visiting www.infliximab.com.

By clicking “continue” below, you will be taken to a Web site that may contain links or references to other Web sites to which our Privacy Policy may not apply. We encourage you to read the Privacy Policy of every Web site you visit.

You are solely responsible for your interactions with such Web sites.

You are leaving Infliximab.com

Thank you for visiting www.infliximab.com.

By clicking “continue” below, you will be taken to a Web site that may contain links or references to other Web sites to which our Privacy Policy may not apply. We encourage you to read the Privacy Policy of every Web site you visit.

You are solely responsible for your interactions with such Web sites.